MP201 / Mitochon Pharma - LARVOL DELTA

Mitochondrial Uncoupler, 2,4-Dinitrophenol, Reduces Spinal Cord Paralysis and Retinal Ganglion Cell Loss in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. (PubMed, Biomolecules) - "Prior studies showed that MP201, a prodrug of 2,4-dinitrophenol (DNP) administered in the experimental autoimmune encephalitis (EAE) mouse model of MS attenuated optic neuritis with preserved vision, increased retinal ganglion cell (RGC) survival, decreased axon loss, and reduced demyelination...DNP treatment significantly reduces RGC loss induced by optic neuritis in EAE mice; however, effects of DNP do not significantly improve visual function, or optic nerve demyelination and inflammation. Current studies show DNP treatment promotes increased RGC survival, but continued inflammation and demyelination likely reduce visual function, suggesting future studies examining combination therapy of DNP with anti-inflammatory agents may be warranted."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Mitochondrial dysfunction following repeated mild blast traumatic brain injury is attenuated by a mild mitochondrial uncoupling prodrug. (PubMed, J Neurotrauma) - "Treatment groups were administered 8 or 80 mg/kg MP201, a prodrug of 2,4 dinitrophenol (DNP) that displays improved pharmacokinetics compared to its metabolized form...However, there was a lack of injury-associated differences in oxidative damage in synaptic mitochondria. Overall, our report demonstrates that rmbTBI results in mitochondrial impairment diffusely throughout the brain and mild mitochondrial uncoupling can restore mitochondrial bioenergetics and oxidative balance."

Journal • CNS Disorders • Metabolic Disorders • Solid Tumor • Vascular Neurology

Mitochon Pharmaceuticals and University of Kentucky Awarded MTEC Grant for MP-201 in Traumatic Brain Injury (Businesswire) - "Mitochon Pharmaceuticals today is pleased to announce the receipt of a $500,000 grant in conjunction with the University of Kentucky for 'Advancement of Drugs for the Treatment of Repeated Mild Traumatic Brain Injury (mTBI)' through a joint funded program by an Alzheimer’s Disease group, BrightFocus Foundation and a military focused foundation, Medical Technology Enterprise Consortium (MTEC). The money will be used to advance Mitochon’s second compound MP-201 through IND enabling studies and provide further evidence that MP-201 can protect brain cells from mild traumatic events that often lead to cognitive issues later in life, such as Alzheimer’s and other dementias."

Commercial • CNS Disorders

[VIRTUAL] Protonophore Amelioration in Huntington’s, Parkinson’s and MS Models, plus Emerging ALS Data: MP101 & prodrug MP201 (NDS 2021) - No abstract available

CNS Disorders • Huntington's Disease • Movement Disorders • Parkinson's Disease

A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson's disease. (PubMed, Neurobiol Aging) - "Amelioration of motor deficits and dopamine neuron loss by MP201 treatment was associated with reductions in microglial and astrocyte activation and neuroinflammation. These preclinical findings suggest the potential application of mitochondrial uncoupling agents such as MP201 as disease-modifying therapies for PD."

Journal • Preclinical • CNS Disorders • Immunology • Movement Disorders • Parkinson's Disease

Disease modifying mitochondrial uncouplers, MP101, and a slow release ProDrug, MP201, in models of Multiple Sclerosis. (PubMed, Neurochem Int) - "This would be a completely novel treatment for MS, targeting the mitochondria directly using a unique platform, mitochondrial uncouplers, that initially act non-genomically based upon biophysics, but cascades into cellular remodeling, neuroprotection and pro-survival. Clinical Phase I testing of MP101 in Normal Healthy Volunteers (NHV) is currently underway allowing for the potential to subsequently evaluate translation in MS patients and other insidious diseases, at expected weight neutral doses."

Journal • CNS Disorders • Immunology • Metabolic Disorders • Multiple Sclerosis

A potent neutralizing site III-specific human antibody neutralizes human metapneumovirus in vivo. (PubMed, J Virol) - "In this report, the isolation and characterization of four new human mAbs, termed MPV196, MPV201, MPV314, and MPV364, are described...We further examined MPV364 in vivo, and found it limits viral replication in BALB/c mice. Altogether, these data provide new mAb candidates for therapeutic development, and provide insights into hMPV vaccine development."

Journal • Preclinical • Immunology • Infectious Disease • Respiratory Diseases

Protonophore Amelioration in Huntington’s,Parkinson’s and MS Models plus Emerging ALS Data: MP101 & prodrug MP201 (NDS 2020) - No abstract available

CNS Disorders • Gene Therapies • Genetic Disorders • Movement Disorders • Parkinson's Disease